Výsledky vyhledávání - Laurie Sherman
- Zobrazuji výsledky 1 - 6 z 6
-
1
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors Autor Geoffrey I. Shapiro, Stewart W. McCallum, Laurel M. Adams, Laurie Sherman, Steve Weller, S. Swann, Harold Keer, Dale Miles, Thomas Müller, Daniel C. Rabe, Franco Cecchi, Donald P. Bottaro, Patricia LoRusso
Vydáno 2015Errata/Corrigenda -
2
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 Autor Joseph P. Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock‐Bryan, Laurie Sherman, Stewart W. McCallum, Elisabeth I. Heath, Scott A. Boerner, Patricia LoRusso
Vydáno 2010Artigo -
3
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study Autor Dirk Schadendorf, Mayur M. Amonkar, Mohammed Milhem, Karen R. Grotzinger, Lev Demidov, Piotr Rutkowski, Claus Garbe, Reinhard Dummer, Jessica C. Hassel, Pascal Wolter, Peter Mohr, Uwe Trefzer, Claudia Lefeuvre‐Plesse, Annemie Rutten, Neil Steven, Gustav Ullenhag, Laurie Sherman, Frank Wu, Kirtan Patel, Michelle Casey, Caroline Robert
Vydáno 2014Artigo -
4
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Autor David P. Steensma, Pierre Fenaux, Koen Van Eygen, Azra Raza, Valeria Santini, Ulrich Germing, Patricia Font, María Díez‐Campelo, Sylvain Thépot, Edo Vellenga, Mrinal M. Patnaik, Jun Ho Jang, Helen Varsos, Jacqueline Bussolari, Esther Rose, Laurie Sherman, Libo Sun, Ying Wan, Souria Dougherty, Fei Huang, Faye Feller, Aleksandra Rizo, Uwe Platzbecker
Vydáno 2020Artigo -
5
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Autor Keith T. Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Reinhard Dummer, Uwe Trefzer, James Larkin, Jochen Utikal, Brigitte Dréno, Marta Nyakas, Mark R. Middleton, Jürgen C. Becker, Michelle Casey, Laurie Sherman, Frank Wu, Danièle Ouellet, Anne‐Marie Martin, Kiran Klaus Patel, Dirk Schadendorf
Vydáno 2012Artigo -
6
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma Autor Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Theodore F. Logan, Andrea Harzstark, Ronald M. Bukowski, Brian I. Rini, Sandy Srinivas, Mark N. Stein, Laurel M. Adams, Lone H. Ottesen, Kevin Laubscher, Laurie Sherman, David F. McDermott, Naomi B. Haas, Keith T. Flaherty, Robert W. Ross, Peter D. Eisenberg, Paul S. Meltzer, Maria J. Merino, Donald P. Bottaro, W. Marston Linehan, Ramaprasad Srinivasan
Vydáno 2012Artigo
Vyhledávací nástroje:
Související témata
Internal medicine
Medicine
Oncology
Gastroenterology
Adverse effect
Chemotherapy
Phases of clinical research
Biology
Cancer
Cell biology
Clinical trial
Kinase
MAPK/ERK pathway
Mucositis
Nausea
Pharmacodynamics
Pharmacokinetics
Pharmacology
Response Evaluation Criteria in Solid Tumors
Trametinib
Urology
Anemia
Aplastic anemia
Biochemistry
Biomarker
Bone marrow
Cancer research
Chemistry
Chemotherapy regimen
Clear cell renal cell carcinoma